Sistema de Salut de Catalunya
Institut Català de la Salut
[Trigo J] HC Marbella International Hospital, Spanish Society of Medical Oncology (SEOM), Marbella, Spain. [García-Cosío M] Ramón y Cajal University Hospital, Spanish Society of Pathological Anatomy (SEAP), Madrid, Spain. [García-Castaño A] Marqués de Valdecilla University Hospital, Spanish Society of Medical Oncology (SEOM), Santander, Spain. [Gomà M] Bellvitge University Hospital, Spanish Society of Pathological Anatomy (SEAP), Hospitalet de Llobregat, Spain. [Mesia-Nin R] Catalan Institute of Oncology (ICO), Badalona Applied Research Group in Oncology, Germans Trias i Pujol Research Institute, Spanish Society of Medical Oncology (SEOM), Badalona, Spain. [Ruiz-Bravo E] La Paz University Hospital, Spanish Society of Pathological Anatomy (SEAP), Madrid, Spain. [Braña-García I] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Society of Medical Oncology (SEOM), Barcelona, Spain. [Alberola-Ferranti M] Vall d’Hebron Hospital Universitari, Spanish Society of Pathological Anatomy (SEAP), Barcelona, Spain
Departament de Salut
2022-09-12T09:54:26Z
2022-09-12T09:54:26Z
2022-10
Epstein Barr virus; Prognosis; Response to treatment
Virus de Epstein Barr; Pronóstico; Respuesta al tratamiento
Virus d'Epstein Barr; Pronòstic; Resposta al tractament
The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.
SEOM and SEAP acknowledge the financial support for this project in the form of unrestricted collaboration in the logistics from AstraZeneca.
Article
Published version
English
Marcadors bioquímics; Glàndules salivals - Càncer; Cap - Càncer; DISEASES::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms; DISEASES::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms::Mouth Neoplasms::Salivary Gland Neoplasms; CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de cabeza y cuello; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de cabeza y cuello::neoplasias de la boca::neoplasias de las glándulas salivales; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
Springer
Clinical and Translational Oncology;24
https://doi.org/10.1007/s12094-022-02856-1
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
